Thrombectomy in Pulmonary Embolism

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity Hospital Plymouth NHS Trust

About this trial

Pulmonary embolism is a blood clot on the lung, which can cause death or significant reduced quality of life. Sucking the clot out with a special tube (catheter) is a relatively new procedure that can be performed but doesn't have the data required to properly support its use in some patients. We know this procedure works in patients who have no other options and would almost certainly die without intervention. We currently don't know how well this procedure is tolerated, how well it works and what its complications are in patients who are moderately to severely unwell. The National Institute of Clinical Excellence (NICE), an advisory body, suggests more data is required to support its use in patients who are sick or very sick. This registry aims to support this growing evidence base to workout if the treatment is effective and the associated risks that come with using it. We are collecting data about this procedure and other treatments patients get offered to better inform clinicians and researchers.

Eligibility criteria

Qualifiers

Clinical signs and symptoms consistent with acute pulmonary embolism with duration of 14 days or less

Patients who present with computed tomography confirmed pulmonary embolism

Defined as intermediate or high-risk pulmonary embolism (according to European Society of Cardiology guidelines)

Date of computed tomography imaging from within a two-year period

Disqualifiers

Known serious, uncontrolled sensitivity to radiographic agents

Computed tomography not available to evaluate pulmonary embolism

Low-risk pulmonary embolism as defined by European Society of Cardiology guidelines

Current participation in another investigational drug or device study that may confound the results of this study. Studies requiring extended follow-up for products that were investigational but have since become commercially available are not considered investigational

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

2,000 Participants
are grouped into 2 trial groups